A study (n=20,146) found SGLT-2 inhibitor use associated with lower recurrence of nephrolithiasis than use of a GLP-1 receptor agonist (1924 [105.3 per 1000 person years] vs 853 [156.4 per 1000 person years] events, respectively; adjusted rate ratio 0.67; 95% CI 0.57-0.79; NNT 20) (1):
- among those with recently active nephrolithiasis, the absolute rate difference was 219 per 1000 person years (NNT of 5)
- gout recurrence was also lower among SGLT-2 inhibitor users with concomitant gout
The study authors concluded that:
- benefits associated with SGLT-2 inhibitor for patients with nephrolithiasis in these target trial emulations suggest they may be a useful addition to current treatments to simultaneously manage nephrolithiasis recurrence and comorbidities, including gout
Reference:
- McCormick N, Yokose C, Lu N, Wexler D J, Aviña-Zubieta J A, De Vera M A et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesBMJ 2024; 387 :e080035